Rani Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: Yahoo! Finance
up to ~$1.1 billion (with options for up to five additional targets) and completed an oversubscribed $60.3 million private placement, raising cash to $49.7 million, eliminating outstanding debt, and extending runway into Q4 2027. RT-114 enters Phase I: Rani initiated a Phase I trial for RT-114 (oral PG-102) in December 2025 after preclinical data showed ~111% relative bioavailability and comparable weight loss versus injected PG-102, with an 8-week Phase I-B in obese patients planned to evaluate weight loss, tolerability, and dosing decisions. Interested in Rani Therapeutics Holdings, Inc.? Here are five stocks we like better. Rani Therapeutics (NASDAQ:RANI) executives highlighted what they described as a “transformational” 2025 during the company's fourth-quarter and full-year earnings call, pointing to progress advancing its oral biologics delivery platform, the launch of a new clinical study, and a new strategic collaboration that helped bolster the balance sheet. Chief Exe
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics (RANI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateGlobeNewswire
- Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationGlobeNewswire
RANI
Earnings
- 3/26/26 - Miss
RANI
Sec Filings
- 3/27/26 - Form 3
- 3/27/26 - Form SCHEDULE
- 3/26/26 - Form S-8
- RANI's page on the SEC website